Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.
2.

Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity.

Chang CY, Tai JA, Li S, Nishikawa T, Kaneda Y.

Oncotarget. 2016 Jul 5;7(27):42195-42207. doi: 10.18632/oncotarget.9743.

3.

Actual status of therapeutic vaccination in non-small cell lung cancer.

Szyszka-Barth K, Ramlau K, Goździk-Spychalska J, Spychalski L, Bryl M, Gołda-Gocka I, Kopczyńska A, Barinow-Wojewódzki A, Ramlau R.

Contemp Oncol (Pozn). 2014;18(2):77-84. doi: 10.5114/wo.2014.42724. Epub 2014 Jun 3. Review.

4.

Immune-checkpoint blockade and active immunotherapy for glioma.

Ahn BJ, Pollack IF, Okada H.

Cancers (Basel). 2013 Nov 1;5(4):1379-412. doi: 10.3390/cancers5041379.

5.

New strategies in Hodgkin lymphoma: better risk profiling and novel treatments.

Diefenbach C, Steidl C.

Clin Cancer Res. 2013 Jun 1;19(11):2797-803. doi: 10.1158/1078-0432.CCR-12-3064. Epub 2013 Feb 27. Review.

6.

Targeting T cells with bispecific antibodies for cancer therapy.

Lum LG, Thakur A.

BioDrugs. 2011 Dec 1;25(6):365-79. doi: 10.2165/11595950-000000000-00000. Review.

7.

Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells.

Swindall AF, Bellis SL.

J Biol Chem. 2011 Jul 1;286(26):22982-90. doi: 10.1074/jbc.M110.211375. Epub 2011 May 5.

8.

Overview of cellular immunotherapy for patients with glioblastoma.

Vauleon E, Avril T, Collet B, Mosser J, Quillien V.

Clin Dev Immunol. 2010;2010. pii: 689171. doi: 10.1155/2010/689171. Epub 2010 Oct 4. Review.

9.

Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.

Yang CR, Guh JH, Teng CM, Chen CC, Chen PH.

Br J Pharmacol. 2009 Aug;157(7):1175-85. doi: 10.1111/j.1476-5381.2009.00237.x. Epub 2009 May 18.

10.

Immunotherapeutic approaches for glioma.

Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M.

Crit Rev Immunol. 2009;29(1):1-42. Review.

11.
12.

Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells.

Sarrabayrouse G, Synaeve C, Leveque K, Favre G, Tilkin-Mariamé AF.

Neoplasia. 2007 Dec;9(12):1078-90.

14.
16.

Mesenchymal stem cells avoid allogeneic rejection.

Ryan JM, Barry FP, Murphy JM, Mahon BP.

J Inflamm (Lond). 2005 Jul 26;2:8.

17.

CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells.

Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME.

EMBO J. 2004 Aug 4;23(15):3175-85. Epub 2004 Jul 22.

18.

Human herpesvirus 8-encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat.

Pati S, Foulke JS Jr, Barabitskaya O, Kim J, Nair BC, Hone D, Smart J, Feldman RA, Reitz M.

J Virol. 2003 May;77(10):5759-73.

19.

Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.

Chopin D, Barei-Moniri R, Maillé P, Le Frère-Belda MA, Muscatelli-Groux B, Merendino N, Lecerf L, Stoppacciaro A, Velotti F.

Am J Pathol. 2003 Apr;162(4):1139-49.

20.

All in the head: obstacles for immune rejection of brain tumours.

Walker PR, Calzascia T, Dietrich PY.

Immunology. 2002 Sep;107(1):28-38. Review. No abstract available.

Supplemental Content

Support Center